Budesonide and ciclesonide: Effect of tissue binding on pulmonary receptor binding

Drug Metabolism and Disposition

Volumn 37, Issue 7, 2009, Pages 1421-1426

  Wu, Kai ^a   Blomgren, Anders L ^b   Ekholm, Kjell ^b   Weber, Benjamin ^a   Edsbaecker, Staffan ^b   Hochhaus, Günther ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CICLESONIDE; GLUCOCORTICOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TISSUE LEVEL; LUNG PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RECEPTOR BINDING;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHODILATOR AGENTS; BUDESONIDE; DIALYSIS; MALE; PLASMA; PREGNENEDIONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID;

RATTUS;

EID: 67649394248     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.026039     Document Type: Article

References (25)

1. Arya V, Issar M, Wang Y, Talton JD, and Hochhaus G (2005) Brain permeability of inhaled corticosteroids. J Pharm Pharmacol 57:1159-1167. (Pubitemid 41391774)
2. Ballard PL (1979) Delivery and transport of glucocorticoids to target cells, in Monograms of Endocrinology, Glucocorticoid Hormone Action (Baxter J and Rousseau G eds) pp 25-48, Springer, Berlin.
3. Barnes NC (2007) The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J 16:149-154. (Pubitemid 46890606)
4. Barnes PJ (1995) Inhaled glucocorticoids for asthma. N Engl J Med 332:868-875.
5. Barth J, Mollmann A, Hochhaus G, Derendorf H, and Mollmann HW (1989) Absorption and transfer of water-soluble glucocorticoids through pulmonary membranes. Atemw-Lungenkrkh 15:412-416. (Pubitemid 19229097)
6. Beato M, Kalimi M, and Feigelson P (1972) Correlation between glucocorticoid binding to specific liver cytosol receptors and enzyme induction in vivo. Biochem Biophys Res Commun 47:1464-1472.
7. Dahlberg E, Thalén A, Brattsand R, Gustafsson JA, Johansson U, Roempke K, and Saartok T (1984) Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Mol Pharmacol 25:70-78. (Pubitemid 14223256)
8. Daley-Yates PT, Harker AJ, Taylor S, and Daniel MJ (2005) Plasma protein binding of corticosteroids: reappraisal of its significance in systemic pharmacological activity (Abstract). J Allergy Clin Immunol 115:S4.
9. Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Sourgens H, and Erdmann M (1995) Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 35:302-305.
10. Diamant A, Eshel M, and Ben-Or S (1975) Interaction of cortisol with the neural retina of the chick embryo in culture. Cell Differ 4:101-112.
11. Druzgala P, Hochhaus G, and Bodor N (1991) Soft drugs-10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol 38:149-154.
12. du Souich P, Verges J, and Erill S (1993) Plasma protein binding and pharmacological response. Clin Pharmacokinet 24:435-440.
13. Esmailpour N, Högger P, and Rohdewald P (2000) Binding of glucocorticoids to human nasal tissue in vitro. Int Arch Allergy Immunol 122:151-154. (Pubitemid 30435690)
14. Hochhaus G (2004) New developments in corticosteroids. Proc Am Thorac Soc 1:269-274.
15. Hochhaus G, Möllmann H, Derendorf H, and Gonzalez-Rothi RJ (1997) Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 37:881-892. (Pubitemid 27514906)
16. Rohatagi S, Arya V, Zech K, Nave R, Hochhaus G, Jensen BK, and Barrett JS (2003) Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43:365-378. (Pubitemid 36372042)
17. Rohatagi S, Krishnaswami S, Pfister M, and Sahasranaman S (2005a) Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. Am J Ther 12:385-397. (Pubitemid 41445135)
18. Rohatagi S, Luo Y, Shen L, Guo Z, Schemm C, Huang Y, Chen K, David M, Nave R, and King SP (2005b) Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 12:201-209. (Pubitemid 40825123)
19. Ryrfeldt A, Andersson P, Edsbäcker S, Tönnesson M, Davies D, and Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 122:86-95. (Pubitemid 13235843)
20. Schmidt S, Banks R, Kumar V, Rand KH, and Derendorf H (2008) Clinical microdialysis in skin and soft tissues: an update. J Clin Pharmacol 48:351-364.
21. Stark J (2001) Pharmacokinetic/Pharmacodynamic Modeling of Corticosteroids and Systemic Effects. Doctoral dissertation, University of Florida, Gainesville, FL.
22. Talbert AM, Tranter GE, Holmes E, and Francis PL (2002) Determination of drug-plasma protein binding kinetics and equilibria by chromatographic profiling: exemplification of the method using L-tryptophan and albumin. Anal Chem 74:446-452. (Pubitemid 34072713)
23. Tayab ZR and Hochhaus G (2007) Advances in single-entity inhaled corticosteroid therapy. Allergy Asthma Proc 28:125-135.
24. Van Der Graaf PH, Van Schaick EA, Math-ot RA, Ijzerman AP, and Danhof M (1997) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther 283:809-816. (Pubitemid 27514643)
25. van Steeg T, Krekels E, Freijer J, Macintyre F, Danhof M and de Lange ECM (2005) The influence of an increase in plasma protein binding on the pharmacokinetics and pharmacodynamics of S (-)-propranolol. PAGE 14th meeting; 2005 Jun 16-17; Pamplona, Spain. Eli Lilly and Company, Ltd., Basingstoke, Hampshire, United Kingdom.